396 related articles for article (PubMed ID: 30732185)
1. Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: A frequentist network meta-analysis.
Zhao Z; Du S; Shen S; Luo P; Ding S; Wang G; Wang L
Medicine (Baltimore); 2019 Feb; 98(6):e14400. PubMed ID: 30732185
[TBL] [Abstract][Full Text] [Related]
2. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
[TBL] [Abstract][Full Text] [Related]
3. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.
Lipinski MJ; Benedetto U; Escarcega RO; Biondi-Zoccai G; Lhermusier T; Baker NC; Torguson R; Brewer HB; Waksman R
Eur Heart J; 2016 Feb; 37(6):536-45. PubMed ID: 26578202
[TBL] [Abstract][Full Text] [Related]
4. Lipid Lowering Therapy and Circulating PCSK9 Concentration.
Nozue T
J Atheroscler Thromb; 2017 Sep; 24(9):895-907. PubMed ID: 28804094
[TBL] [Abstract][Full Text] [Related]
5. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
[TBL] [Abstract][Full Text] [Related]
6. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
[TBL] [Abstract][Full Text] [Related]
7. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis.
Khan SU; Yedlapati SH; Lone AN; Hao Q; Guyatt G; Delvaux N; Bekkering GET; Vandvik PO; Riaz IB; Li S; Aertgeerts B; Rodondi N
BMJ; 2022 May; 377():e069116. PubMed ID: 35508321
[TBL] [Abstract][Full Text] [Related]
8. Reduction of C-reactive protein, low-density lipoprotein cholesterol, and its relationship with cardiovascular events of different lipid-lowering therapies: A systematic review and meta-analysis of randomized controlled trials.
Yang W; Cai X; Lin C; Lv F; Zhu X; Han X; Ji L
Medicine (Baltimore); 2022 Sep; 101(37):e30563. PubMed ID: 36123891
[TBL] [Abstract][Full Text] [Related]
9. Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression.
Masson W; Lobo M; Siniawski D; Molinero G; Masson G; Huerín M; Nogueira JP
Lipids Health Dis; 2020 May; 19(1):111. PubMed ID: 32460779
[TBL] [Abstract][Full Text] [Related]
10. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
[TBL] [Abstract][Full Text] [Related]
11. Relative Effect of Current Intensive Lipid-Lowering Drugs on Cardiovascular Outcomes in Secondary Prevention - A Meta-Analysis of 12 Randomized Trials.
Wang S; Xiu J; Liao W; Liao Y; Bin J
Circ J; 2019 May; 83(6):1356-1367. PubMed ID: 31006730
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease.
Suh DC; Griggs SK; Henderson ER; Lee SM; Park T
Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):51-69. PubMed ID: 29148854
[TBL] [Abstract][Full Text] [Related]
13. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
[TBL] [Abstract][Full Text] [Related]
14. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.
Koskinas KC; Siontis GCM; Piccolo R; Mavridis D; Räber L; Mach F; Windecker S
Eur Heart J; 2018 Apr; 39(14):1172-1180. PubMed ID: 29069377
[TBL] [Abstract][Full Text] [Related]
15. Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial.
Nissen SE; Dent-Acosta RE; Rosenson RS; Stroes E; Sattar N; Preiss D; Mancini GB; Ballantyne CM; Catapano A; Gouni-Berthold I; Stein EA; Xue A; Wasserman SM; Scott R; Thompson PD;
Clin Cardiol; 2016 Mar; 39(3):137-44. PubMed ID: 26946077
[TBL] [Abstract][Full Text] [Related]
16. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
Wójcik C
Postgrad Med; 2017 Nov; 129(8):801-810. PubMed ID: 28879791
[TBL] [Abstract][Full Text] [Related]
17. Current status of lipid management in acute coronary syndrome.
Fujisue K; Tsujita K
J Cardiol; 2017 Aug; 70(2):101-106. PubMed ID: 28325524
[TBL] [Abstract][Full Text] [Related]
18. PCSK9 Inhibitors: From Nature's Lessons to Clinical Utility.
Raal FJ; Chilton R; Ranjith N; Rambiritch V; Leisegang RF; Ebrahim IO; Tonder AV; Shunmoogam N; Bouharati C; Musa MG; Karamchand S; Naidoo P; Blom DJ
Endocr Metab Immune Disord Drug Targets; 2020; 20(6):840-854. PubMed ID: 32053090
[TBL] [Abstract][Full Text] [Related]
19. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
20. Clinical Pharmacology of Statins: an Update.
Ferri N; Corsini A
Curr Atheroscler Rep; 2020 Jun; 22(7):26. PubMed ID: 32494971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
